Oral infigratinib in PROPEL 3 shows favorable 52-week trends in children
In PROPEL 3, oral infigratinib treatment for 52 weeks showed favorable trends versus placebo on clinically meaningful exploratory endpoints, including sleep apnea and otitis media events.
Treatment with oral infigratinib for 52 weeks in PROPEL 3 showed favorable trends versus placebo across clinically meaningful exploratory endpoints, including sleep apnea and otitis media events. In children treated for up to three years in the PROPEL program, oral infigratinib demonstrated sustained benefits.